APA (7th ed.) Citation

Holle, S. L. D., Kunkel, J. B., Hassager, C., Pecini, R., Wiberg, S., Palm, P., . . . Frydland, M. (2024). Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): Study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial. Trials, 25(1), 1. https://doi.org/10.1186/s13063-024-08567-y

Chicago Style (17th ed.) Citation

Holle, Sarah Louise Duus, et al. "Low-dose Dobutamine in Acute Myocardial Infarction with Intermediate to High Risk of Cardiogenic Shock Development (the DOBERMANN-D Trial): Study Protocol for a Double-blinded, Placebo-controlled, Single-center, Randomized Clinical Trial." Trials 25, no. 1 (2024): 1. https://doi.org/10.1186/s13063-024-08567-y.

MLA (9th ed.) Citation

Holle, Sarah Louise Duus, et al. "Low-dose Dobutamine in Acute Myocardial Infarction with Intermediate to High Risk of Cardiogenic Shock Development (the DOBERMANN-D Trial): Study Protocol for a Double-blinded, Placebo-controlled, Single-center, Randomized Clinical Trial." Trials, vol. 25, no. 1, 2024, p. 1, https://doi.org/10.1186/s13063-024-08567-y.